Physician profile
Athar M Saeed
NPI 1639348881
$4,748.39
in general payments reported to CMS, 2019-2025
12 companies · $29.88 in 2025
The $29.88 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $62.89 · 2021: $17.78 · 2022: $1,351 · 2023: $10.03 · 2024: $1,931 · 2025: $29.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,372 · Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,372.01 |
| Food and Beverage | $598.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,947.58 | 2019-2024 | Indigo System |
| Medtronic Vascular, INC. | $339.01 | 2019 | |
| Siemens Medical Solutions USA, INC. | $227.00 | 2024 | |
| Novo Nordisk INC | $46.25 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $44.06 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $37.24 | 2022-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $29.88 | 2025 | Onpattro |
| Pfizer INC. | $18.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.63 | 2019 | |
| Cardiovascular Systems INC. | $16.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.34 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.03 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athar Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.